Michael J Koren

Summary

Publications

  1. ncbi Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study
    Michael J Koren
    Jacksonville Center for Clinical Research, Jacksonville, Florida, USA
    J Am Coll Cardiol 44:1772-9. 2004
  2. doi Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD
    Michael J Koren
    Jacksonville Center for Clinical Research, Jacksonville, FL 32216, USA
    Am J Kidney Dis 53:741-50. 2009
  3. ncbi Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE)
    Michael J Koren
    Jacksonville Center for Clinical Research, Jacksonville, Florida 32216, USA
    J Am Coll Cardiol 49:1027-34. 2007
  4. ncbi Statin use in a "real-world" clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial
    Michael J Koren
    Jacksonville Center for Clinical Research, Jacksonville, Florida 32216, USA
    Am J Med 118:16-21. 2005
  5. ncbi Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial
    Michael J Koren
    Jacksonville Center for Clinical Research, Jacksonville, FL M J K TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA R P G, M S S Carbohydrate and Lipid Metabolism Research Unit, Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa F J R Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Camperdown, Australia D S Bethesda Health Research Center, Bethesda, MD M B Lipid Clinic, Oslo University Hospital, Oslo, Norway G L Hospital Universitario Miguel Servet, Zaragoza, Spain F C and Amgen Inc, Thousand Oaks, CA R S, p n, T L, R S, S M W
    Circulation 129:234-43. 2014
  6. ncbi Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab
    Michael J Koren
    Jacksonville Center for Clinical Research, Jacksonville, Florida Electronic address
    J Am Coll Cardiol 63:2531-40. 2014
  7. doi Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
    Michael J Koren
    Jacksonville Center for Clinical Research, FL, USA
    Lancet 380:1995-2006. 2012
  8. doi Impact of high-dose atorvastatin in coronary heart disease patients age 65 to 78 years
    Michael J Koren
    Jacksonville Center for Clinical Research, Jacksonville, Florida, USA
    Clin Cardiol 32:256-63. 2009
  9. doi Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia
    Michael J Koren
    Jacksonville Center for Clinical Research, Jacksonville, FL, USA
    Am J Health Syst Pharm 68:818-27. 2011
  10. ncbi Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective
    Robert J Straka
    University of Minnesota, Minneapolis, MN, USA
    Curr Med Res Opin 23:1517-29. 2007

Detail Information

Publications12

  1. ncbi Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study
    Michael J Koren
    Jacksonville Center for Clinical Research, Jacksonville, Florida, USA
    J Am Coll Cardiol 44:1772-9. 2004
    ....
  2. doi Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD
    Michael J Koren
    Jacksonville Center for Clinical Research, Jacksonville, FL 32216, USA
    Am J Kidney Dis 53:741-50. 2009
    ....
  3. ncbi Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE)
    Michael J Koren
    Jacksonville Center for Clinical Research, Jacksonville, Florida 32216, USA
    J Am Coll Cardiol 49:1027-34. 2007
    ..This report describes safety and tolerability data from 746 chronic angina patients treated in the ROLE (Ranolazine Open Label Experience) program...
  4. ncbi Statin use in a "real-world" clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial
    Michael J Koren
    Jacksonville Center for Clinical Research, Jacksonville, Florida 32216, USA
    Am J Med 118:16-21. 2005
    ..These results indicate that usual-care treatment was not equivalent to targeted statin therapy, even in a trial conducted to minimize potential bias owing to traditional patient selection and trial design methods...
  5. ncbi Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial
    Michael J Koren
    Jacksonville Center for Clinical Research, Jacksonville, FL M J K TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA R P G, M S S Carbohydrate and Lipid Metabolism Research Unit, Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa F J R Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Camperdown, Australia D S Bethesda Health Research Center, Bethesda, MD M B Lipid Clinic, Oslo University Hospital, Oslo, Norway G L Hospital Universitario Miguel Servet, Zaragoza, Spain F C and Amgen Inc, Thousand Oaks, CA R S, p n, T L, R S, S M W
    Circulation 129:234-43. 2014
    ..The longer-term efficacy and safety of PCSK9 inhibition remain undefined...
  6. ncbi Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab
    Michael J Koren
    Jacksonville Center for Clinical Research, Jacksonville, Florida Electronic address
    J Am Coll Cardiol 63:2531-40. 2014
    ..The aim of this study was to compare biweekly and monthly evolocumab with placebo and oral ezetimibe in patients with hypercholesterolemia in a phase III trial...
  7. doi Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
    Michael J Koren
    Jacksonville Center for Clinical Research, FL, USA
    Lancet 380:1995-2006. 2012
    ..We assessed the effects of AMG 145, a human monoclonal antibody against PCSK9, in patients with hypercholesterolaemia in the absence of concurrent lipid-lowering treatment...
  8. doi Impact of high-dose atorvastatin in coronary heart disease patients age 65 to 78 years
    Michael J Koren
    Jacksonville Center for Clinical Research, Jacksonville, Florida, USA
    Clin Cardiol 32:256-63. 2009
    ..High-dose statin therapy may be underutilized in aged patients due to doubts about efficacy and safety...
  9. doi Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia
    Michael J Koren
    Jacksonville Center for Clinical Research, Jacksonville, FL, USA
    Am J Health Syst Pharm 68:818-27. 2011
    ..The efficacy and safety of conivaptan administered via 30-minute i.v. infusion to patients with euvolemic or hypervolemic hyponatremia were evaluated...
  10. ncbi Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective
    Robert J Straka
    University of Minnesota, Minneapolis, MN, USA
    Curr Med Res Opin 23:1517-29. 2007
    ..The present analysis modeled the clinical and economic consequences of initiating atorvastatin versus generic simvastatin in defined US managed care organization patient populations...
  11. ncbi Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia
    Jalal K Ghali
    Division of Cardiology, Wayne State University, 4201 St Antoine, Detroit, Michigan 48201, USA
    J Clin Endocrinol Metab 91:2145-52. 2006
    ..Hyponatremia [serum sodium concentration ([Na(+)]), <135 mEq/liter] is the most common fluid and electrolyte abnormality among hospitalized patients. It is frequently caused by the inappropriate release of arginine vasopressin...
  12. ncbi Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial
    John D Parker
    Department of Medicine, University Health Network and Mount Sinai Hospitals, University of Toronto, Ontario, Canada
    Crit Care Med 35:1863-8. 2007
    ..g., sildenafil) might need intravenous nitroglycerin (NTG) treatment. This study determined if, and at what dose, intravenous NTG could be administered safely to men with coronary artery disease who had recently ingested sildenafil...